ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	2.82B
Revenue (ttm)	726.44M
Net Income (ttm)	-61.29M
Shares Out	164.77M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	25.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,843,205
Open	16.90
Previous Close	16.71
Day's Range	16.86 - 17.57
52-Week Range	16.16 - 33.99
Beta	0.39
Analysts	Buy
Price Target	30.90 (+80.7%)
Earnings Date	May 8, 2024

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 598
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD

Financial Performance

In 2023, ACAD's revenue was $726.44 million, an increase of 40.45% compared to the previous year's $517.24 million. Losses were -$61.29 million, -71.62% less than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $30.9, which is an increase of 80.70% from the latest price.

Price Target

$30.9

(80.70% upside)

Analyst Consensus: Buy